AUS
NZ
UK
CA
USA
IND
_10_04_2024_16_38_50_427275.jpg)
Highlights
- Osteopore (OSX) receives European approval for specialized implants.
- Projected growth driven by demand in cranial and orthopaedic markets.
- Exclusive distribution partnership established with Zimmer Biomet.
Osteopore (ASX:OSX), a pioneer in regenerative medicine, has recently achieved a significant milestone by obtaining European Union medical device regulation approval for its custom orthopaedic and cranial implants. This approval opens new doors for the company to supply high-value, custom-made implants to the European market, enhancing its existing array of standard neurosurgical and craniofacial products.
This strategic development is expected to bolster Osteopore’s market presence by partnering with Zimmer Biomet, a major player in orthopaedic solutions from the United States. The collaboration is set to introduce these advanced medical solutions to a broader audience, potentially leading to new revenue streams for Osteopore (OSX).
Dr. Yujing Lim, Chief Executive Officer of Osteopore, highlighted the significance of this approval as a key element of the company’s strategy to improve access to innovative medical solutions. "The approval for our custom cranial implants not only deepens our partnership with Zimmer Biomet but also enables us to extend the reach of our advanced implant technology across Europe," Dr. Lim explained.
The European market for custom cranial implants currently stands at $618.4 million and is anticipated to grow at a compound annual growth rate of 9.4% through 2030. This growth is largely fueled by an increase in cranial surgeries resulting from road accidents, sports injuries, and medical conditions like brain tumors. Additionally, the market for custom orthopaedic implants is projected to reach a staggering $26.7 billion by 2029, driven by an aging population and a surge in demand for technologies that enhance mobility and reduce recovery times after surgery.
In a related development, Osteopore has entered into a five-year sales and marketing agreement with DiethelmKellerSiberHegner (DKSH) to promote its standard orthopaedic products in Singapore, spotlighting the high tibial osteotomy product aimed at supporting knee preservation surgeries. This agreement is particularly significant given the doubling of such surgeries at Singapore General Hospital from 50 in 2020 to about 100 in 2021.
The expansion into Singapore and the European regulatory approval represent key elements in Osteopore's strategy to enhance global access to its innovative medical solutions, demonstrating the company’s commitment to improving patient outcomes and expanding its market footprint through strategic partnerships and regulatory achievements.
